Stocktoria
Protara Therapeutics, Inc. TARA
Protara Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D expense | $42.6M | $31.7M | $25.0M | $16.8M | $21.1M | $12.0M | $3.9M | $11.8M | $21.7M | $18.9M |
| Operating income | -$64.5M | -$49.2M | -$43.6M | -$67.1M | -$47.5M | -$34.4M | -$7.8M | -$21.4M | -$30.4M | -$28.7M |
| Interest expense | — | — | — | — | $0 | $34,000 | — | — | — | — |
| Net income | -$57.4M | -$44.6M | -$40.4M | -$66.0M | -$47.3M | -$34.0M | -$7.8M | -$20.7M | -$30.0M | -$28.5M |
| EPS (diluted) | $-1.34 | $-2.17 | $-3.57 | $-5.86 | $-4.21 | — | — | — | — | — |
| Operating cash flow | -$56.4M | -$35.8M | -$37.6M | -$26.5M | -$34.5M | -$23.4M | -$5.0M | -$23.2M | -$22.4M | -$23.7M |
| Free cash flow | -$56.5M | -$35.9M | -$37.6M | -$26.6M | -$35.1M | -$24.3M | -$5.5M | -$23.4M | -$22.4M | -$24.0M |
| Cash & equivalents | $49.7M | $162.8M | $39.6M | $24.1M | $35.7M | $168.6M | $564,000 | $19.4M | $21.2M | $36.4M |
| Total assets | $209.5M | $181.5M | $79.0M | $113.3M | $172.6M | $203.2M | $1.2M | $23.5M | $44.0M | $43.5M |
| Total liabilities | $13.1M | $14.3M | $10.6M | $11.2M | $10.7M | $3.9M | $3.4M | $3.1M | $9.2M | $5.1M |
| Shareholders' equity | $196.4M | $167.1M | $68.3M | $102.1M | $161.9M | $199.2M | -$2.1M | $4.8M | $34.7M | $38.4M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.